Goldman Sachs Group Inc Enanta Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 160,133 shares of ENTA stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
160,133
Previous 84,811 88.81%
Holding current value
$1.37 Million
Previous $1.1 Million 51.05%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$10.05 - $16.54 $756,986 - $1.25 Million
75,322 Added 88.81%
160,133 $1.66 Million
Q2 2024

Aug 13, 2024
SELL
$11.43 - $17.02 $67,196 - $100,060
-5,879 Reduced 6.48%
84,811 $1.1 Million
Q1 2024

May 15, 2024
SELL
$10.08 - $17.46 $967,186 - $1.68 Million
-95,951 Reduced 51.41%
90,690 $1.58 Million
Q4 2023

Feb 13, 2024
SELL
$8.18 - $10.78 $861,239 - $1.13 Million
-105,286 Reduced 36.07%
186,641 $1.76 Million
Q3 2023

May 14, 2024
BUY
$11.09 - $22.13 $1.17 Million - $2.33 Million
105,286 Added 56.41%
291,927 $3.26 Million
Q3 2023

Nov 14, 2023
BUY
$11.09 - $22.13 $586,195 - $1.17 Million
52,858 Added 22.11%
291,927 $3.26 Million
Q2 2023

May 14, 2024
BUY
$20.68 - $39.85 $185,685 - $357,813
8,979 Added 3.9%
239,069 $5.12 Million
Q2 2023

Aug 14, 2023
BUY
$20.68 - $39.85 $185,685 - $357,813
8,979 Added 3.9%
239,069 $5.12 Million
Q1 2023

May 14, 2024
SELL
$38.82 - $54.59 $207,919 - $292,384
-5,356 Reduced 2.27%
230,090 $9.3 Million
Q1 2023

May 11, 2023
SELL
$38.82 - $54.59 $207,919 - $292,384
-5,356 Reduced 2.27%
230,090 $9.3 Million
Q4 2022

May 14, 2024
BUY
$40.77 - $53.73 $2.48 Million - $3.27 Million
60,851 Added 34.85%
235,446 $11 Million
Q4 2022

Feb 13, 2023
BUY
$40.77 - $53.73 $2.48 Million - $3.27 Million
60,851 Added 34.85%
235,446 $11 Million
Q3 2022

May 14, 2024
BUY
$48.29 - $71.27 $1.75 Million - $2.58 Million
36,239 Added 26.19%
174,595 $9.06 Million
Q3 2022

Nov 10, 2022
BUY
$48.29 - $71.27 $1.75 Million - $2.58 Million
36,239 Added 26.19%
174,595 $9.06 Million
Q2 2022

May 14, 2024
SELL
$38.13 - $76.93 $1.84 Million - $3.71 Million
-48,285 Reduced 25.87%
138,356 $6.54 Million
Q2 2022

Aug 15, 2022
BUY
$38.13 - $76.93 $1.44 Million - $2.91 Million
37,855 Added 37.67%
138,356 $6.54 Million
Q1 2022

May 16, 2022
SELL
$56.06 - $74.11 $1.07 Million - $1.42 Million
-19,150 Reduced 16.0%
100,501 $7.15 Million
Q4 2021

Feb 14, 2022
BUY
$60.19 - $97.37 $1.04 Million - $1.69 Million
17,319 Added 16.92%
119,651 $8.95 Million
Q3 2021

Nov 10, 2021
BUY
$41.02 - $58.65 $4.2 Million - $6 Million
102,332 New
102,332 $5.81 Million

Others Institutions Holding ENTA

# of Institutions
110
Shares Held
21.1M
Call Options Held
4.8K
Put Options Held
4.6K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $178M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email